Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs Wynn Resorts, Limited (WYNN) Price & Performance

Quest Diagnostics IncTrade
Wynn Resorts, LimitedTrade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs Wynn Resorts, Limited — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Wynn Resorts, Limited trades at $75.15 (market cap $7.75B). The key difference: Quest Diagnostics Inc is far larger — about 3.3× Wynn Resorts, Limited's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Wynn Resorts, Limited for 76 Days on average.

DGXWYNN
Market Cap
$25.48B$7.75B
Volume
941,8662,243,813
Sector
HealthConsumer Cyclical
52-Week High
$247.45$133.09
52-Week Low
$173.49$74.97
Typical Hold Time
56 Days76 Days
Enterprise Value
$31.23B$17.99B
Dividend Yield
1.49%1.33%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.

The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.

Wynn Resorts, Limited

Wynn Resorts trades at $75.29, up 0.43% on the day, with a bearish technical signal from moving averages and mixed oscillators. The company reported Q2 2026 EPS of $1.24, beating expectations, driven by Macau strength, but faces margin pressure in the U.S. and rising capital expenditure for new projects. Revenue for 2025 was $7.14 billion with a net income margin of 4.58%, while the balance sheet shows high long-term debt of $10.50 billion and negative shareholder equity.

The outlook is mixed: analyst consensus is bullish with a $132.36 price target, but risks include high leverage, project costs, and competitive pressures. Upside hinges on Macau recovery and successful project execution, while downside risks stem from debt servicing and macroeconomic volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX →

About Wynn Resorts, Limited

Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.

Read more on WYNN →